https://www.selleckchem.com/pr....oducts/myf-01-37.htm
ffusions that newly occur after CAR T therapy can generally be managed medically and tend not to persist.Until recently, treatment options were relatively limited for children and young adults with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). Tisagenlecleucel is a chimeric antigen receptor T cell (CAR-T) immunotherapy with promising efficacy and manageable safety that was approved in Japan in 2019 for the treatment of CD19-positive r/r B cell ALL (B-ALL). However, there is no publication assessing the cost-effectiv
Like
Comment
Share
